Make your money go further for just 25p per day

A catastrophic few months, but a glimmer of hope for Immunodiagnostic Systems Holdings (AIM: IDH)?

24/06/2015 · Immunodiagnostic Systems (IDH) 

Immunodiagnostic Systems (IDS) is engaged in the research and development of medical diagnostics as well as the manufacture and distribution of diagnostic products. The Group supply specialist immunoassay kits and automated immune analyser technologies for use in research, medical and pharmaceutical applications. 

Founded in 1977, initially the Group specialised in calcium metabolism, bone disease and Vitamin D detection, and their high margin manual tests brought in a nice amount of cash. The company listed on AIM in 2004 at 51p per share, and by 2010 shares were valued at 800p. They grew both organically and via acquisitions to expand their offering, which initially helped to drive up sales and made for a successful company. In 2009 they…

Sign up and read the full article

Register to continue reading our content.

Get FREE access now

Already a member? Login


Previous article Next article

DON'T MISS OUT!

Get top investment ideas to help safeguard and grow your wealth.

Invaluable insight from the exciting world of smaller companies.

REGISTER FREE

DON'T MISS OUT ON OUR PREMIUM CONTENT

Become a champion investor for just £90 a year. Benefit from our high performing portfolios:

START FREE TRIAL

More on Immunodiagnostic Systems

Coronavirus impact: 30 June - new Covid-19 test is great news

30/06/2020 · Company Insights

News today includes the launch of a new Covid-19 antibody test from an AIM quoted group…


Coronavirus impact: 17 June - Best of the Best receives takeover interest

17/06/2020 · Company Insights

Best of the Best announces a preliminary approach and boohoo continues to grow strongly over lockdown -…


More Company Insights

Elderly challenges | Demotion | Australian boost

21/11/2024 · Churchill China · CVS Group · Renold · Tracsis

Bonkers Bargains: poised to recover with a new CEO

20/11/2024 · James Cropper

Improving returns | Questionable business models

Sign-up to our free email updates

SIGN UP